Evidence map›Paper›PMID 34345415›Full record

ArticleClinical kidney journal2021

Survival with low- and high-flux dialysis.

Emilio Sánchez-Álvarez, Minerva Rodríguez-García, Francesco Locatelli, Carmine Zoccali, Alejandro Martín-Malo, Jürgen Floege, Markus Ketteler, Gerard London, José L Górriz, Boleslaw Rutkowski and 5 more

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 5 countries.

Emilio Sánchez-ÁlvarezDepartment of Nephrology, Hospital Universitario de Cabueñes, REDinREN del ISCIII, Gijón, Spain.
Minerva Rodríguez-GarcíaDepartment of Nephrology, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Spain.
Francesco LocatelliDepartment of Nephrology, Dialysis and Renal Transplant, Alessandro Manzoni Hospital, Lecco, Italy.
Carmine ZoccaliCNR National Research Council (Italy), Clinical Epidemiology and Physiopathology of Renal Disease and Hypertension and Renal and Transplantation Unit, Ospedali Riuniti, Ancona, Italy.
Alejandro Martín-MaloNephrology Service, University Hospital Reina Sofia, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), University of Cordoba, REDinREN del ISCIII, Córdoba, Spain.
Jürgen FloegeDepartment of Nephrology and Clinical Immunology, RWTH Aachen University, Aachen, Germany.
Markus KettelerDepartment of General Internal Medicine and Nephrology Stuttgart, Robert-Bosch-Krankenhaus GmbH, Baden-Württemberg, Germany.
Gerard LondonCentre Hospitalier FH Manhes, Fleury-Mérogis, France.
José L GórrizDepartment of Nephrology, Hospital Clinico Universitario, Valencia, Spain.ORCID https://orcid.org/0000-0002-1134-9051
Boleslaw RutkowskiDepartment of Nephrology, Transplantology and Internal Medicine, Gdańsk Medical University, Gdańsk, Poland.
Anibal FerreiraNephrology Department, Hospital Curry Cabral and Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.
Drasko PavlovicDepartment of Nephrology and Dialysis, Sestre Milosrdnice University Hospital, Zagreb, Croatia.
Jorge B Cannata-AndíaBone and Mineral Research Unit, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), REDinREN del ISCIII, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.
José L Fernández-MartínDepartment of Nephrology and Dialysis, Sestre Milosrdnice University Hospital, Zagreb, Croatia.ORCID https://orcid.org/0000-0003-3455-1778
COSMOS group
Hospital Universitario Central de Asturias · ESAlessandro Manzoni Hospital · ITGdańsk Medical University · PLHospital Curry Cabral · PTHospital Universitario De Cabueñes · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ESNational Research Council · ITRobert Bosch Hospital · DERWTH Aachen University · DEUniversidad de Oviedo · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBesides advances in haemodialysis (HD), mortality rates are still high. The effect of the different types of HD membranes on survival is still a controversial issue. The aim of this COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) analysis was to survey, in HD patients, the relationship between the use of conventional low- or high-flux membranes and all-cause and cardiovascular mortality.

methodsCOSMOS is a multicentre, open-cohort, 3-year prospective study, designed to evaluate mineral and bone disorders in the European HD population. The present analysis included 5138 HD patients from 20 European countries, 3502 randomly selected at baseline (68.2%), plus 1636 new patients with <1 year on HD (31.8%) recruited to replace patients who died, were transplanted, switched to peritoneal dialysis or lost to follow-up by other reasons. Cox-regression analysis with time-dependent variables, propensity score matching and the use of an instrumental variable (facility-level analysis) were used.

resultsAfter adjustments using three different multivariate models, patients treated with high-flux membranes showed a lower all-cause and cardiovascular mortality risks {hazard ratio (HR) = 0.76 [95% confidence interval (CI) 0.61-0.96] and HR = 0.61 (95% CI 0.42-0.87), respectively}, that remained significant after matching by propensity score for all-cause mortality (HR = 0.69, 95% CI 0.52-0.93). However, a facility-level analysis showed no association between the case-mix-adjusted facility percentage of patients dialysed with high-flux membranes and all-cause and cardiovascular mortality.

conclusionsHigh-flux dialysis was associated with a lower relative risk of all-cause and cardiovascular mortality. However, dialysis facilities using these dialysis membranes to a greater extent did not show better survival.

Indexed as

chronic haemodialysisdialysisdialysis membranesmortalitymortality risk

Identifiers

PMID34345415
PMCPMC8323142
OpenAlexW3116979536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.